Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.45 |
| ▸ | CA2 | P00918 | 3/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.45 |
| ▸ | KIF11 | P52732 | 2/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | STS | P08842 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | DRD5 | P21918 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3575587 | 1.00 | CXCR2 (0.46) | CXCR2CA1CA2CA9CXCR1 | |
| SCHEMBL1820549 | 1.00 | CXCR2 (0.46) | CXCR2CA1CA2CA9CXCR1 | |
| SCHEMBL28797392 | 0.95 | CXCR2 (0.49) | CXCR2CA1CA2CA9CXCR1 | |
| SCHEMBL3574727 | 0.87 | CXCR2 (0.48) | CXCR2CA1CA2CA9CXCR1 | |
| SCHEMBL1819925 | 0.87 | CXCR2 (0.48) | CXCR2CA1CA2CA9CXCR1 | |
| SCHEMBL3582579 | 0.87 | CXCR2 (0.48) | CXCR2CA1CA2CA9CXCR1 | |
| SCHEMBL3578500 | 0.86 | CXCR2 (0.45) | CXCR2CA1CA2CA9CXCR1 | |
| SCHEMBL3582529 | 0.82 | CXCR2 (0.45) | CXCR2CA1CA2CA9CXCR1 | |
| SCHEMBL3584598 | 0.81 | CXCR2 (0.47) | CXCR2CA1CA2CA9CXCR1 | |
| SCHEMBL3575250 | 0.80 | CXCR2 (0.43) | CXCR2CA1CA2CA9CXCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440711-B2 | 2-aryl-2-fluoropropanoic acids and derivatives and pharmaceutical compositions containing them | DOMPE PHA.R.MA S.P.A. (IT) | 2013-05-14 | — | — | US | claimed |
| EP-2094638-B1 | 2-ARYL-2-FLUOROPROPANOIC ACIDS AND DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE SPA (IT) | 2012-08-08 | — | — | EP | claimed |
| US-20100076034-A1 | 2-ARYL-2-FLUOROPROPANOIC ACIDS AND DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE PHA.R.MA S.P.A. (IT) | 2010-03-25 | — | — | US | claimed |
| EP-2094638-A2 | 2-ARYL-2-FLUOROPROPANOIC ACIDS AND DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE' pha.r.ma s.p.a. (IT) | 2009-09-02 | — | — | EP | claimed |
| WO-2008075184-A2 | 2-ARYL-2-FLUOROPROPANOIC ACIDS AND DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE' PHA.R.MA S.P.A. (IT) | 2008-06-26 | — | — | WO | claimed |
| US-8440711-B2 | 2-aryl-2-fluoropropanoic acids and derivatives and pharmaceutical compositions containing them | DOMPE PHA.R.MA S.P.A. (IT) | 2013-05-14 | — | — | US | disclosed |
| US-8440711-B2 | 2-aryl-2-fluoropropanoic acids and derivatives and pharmaceutical compositions containing them | DOMPE PHA.R.MA S.P.A. (IT) | 2013-05-14 | — | — | US | disclosed |
| US-8440711-B2 | 2-aryl-2-fluoropropanoic acids and derivatives and pharmaceutical compositions containing them | DOMPE PHA.R.MA S.P.A. (IT) | 2013-05-14 | — | — | US | disclosed |
| EP-2094638-B1 | 2-ARYL-2-FLUOROPROPANOIC ACIDS AND DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE SPA (IT) | 2012-08-08 | — | — | EP | disclosed |
| EP-2094638-B1 | 2-ARYL-2-FLUOROPROPANOIC ACIDS AND DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE SPA (IT) | 2012-08-08 | — | — | EP | disclosed |
| US-20100076034-A1 | 2-ARYL-2-FLUOROPROPANOIC ACIDS AND DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE PHA.R.MA S.P.A. (IT) | 2010-03-25 | — | — | US | disclosed |
| US-20100076034-A1 | 2-ARYL-2-FLUOROPROPANOIC ACIDS AND DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE PHA.R.MA S.P.A. (IT) | 2010-03-25 | — | — | US | disclosed |
| US-20100076034-A1 | 2-ARYL-2-FLUOROPROPANOIC ACIDS AND DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE PHA.R.MA S.P.A. (IT) | 2010-03-25 | — | — | US | disclosed |
| EP-2094638-A2 | 2-ARYL-2-FLUOROPROPANOIC ACIDS AND DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE' pha.r.ma s.p.a. (IT) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008075184-A2 | 2-ARYL-2-FLUOROPROPANOIC ACIDS AND DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE' PHA.R.MA S.P.A. (IT) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008075184-A2 | 2-ARYL-2-FLUOROPROPANOIC ACIDS AND DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE' PHA.R.MA S.P.A. (IT) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076034-A1 | 2-ARYL-2-FLUOROPROPANOIC ACIDS AND DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FPR2, FPR3, FPR1 | CXCR2 33/4885CA1 3830/4885CA2 1312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.